AstraZeneca shares slump after Phase 3 lung cancer drug study

AstraZeneca shares fell Monday after a late-stage study on a lung cancer drug disappointed investors.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.